Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement: A Randomized, Enoxaparin-controlled, Open Label, Dose-escalation Study

NCT00408239 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00408239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00408239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement: A Randomized, Enoxaparin-controlled, Open Label, Dose-escalation Study
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2006
Completion date
March 31, 2009
Enrollment
367 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

thromboembolism